Rigel Pharmaceuticals (RIGL) Peer Comparison

$46.44

$-0.43 (-0.91%)

As on 28-Aug-2026 13:31EDT

Market cap

$857 Mln

Revenue (TTM)

$277 Mln

P/E Ratio

2.7

P/B Ratio

2

Div. Yield

0 %

Edit

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	857	17,326	16,614	13,400	12,305
Revenue ($ Mln)	277	2,782	1,054	2,436	670
Net Profit ($ Mln)	321.91	491.50	755.85	860.62	-319.95
Net Margin (%)	116.30	17.67	71.69	35.33	-47.79
RoE (%)	78.81	110.09	--	42.98	-71.14
Price to Earnings	2.72	36.49	19.38	17.01	--
Price-To-Book	2.02	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	276.79	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	23.84	1,982.07	103.47	85.67	19.14
Gross Profit	274.66	760.62	588.53	2,236.43	829.45
Operating Expenses	165.90	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	87.05	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	85.58	598.92	101.11	1,035.47	-252.08
Provision for Tax	-236.33	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	321.91	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	425.42	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	0.06	187.89	384.48	288.55	1,362.63
Current Liabilities	95.36	1,435.43	464.70	361.93	283.35
Total Liabilities	513.59	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	335.54	1,006.90	895.24	1,243.41	440.60
Current Assets	185.53	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	513.59	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	39.95	120.10	449.89	165.93	864.07
Net Current Assets	89.94	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	75.66	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	-92.37	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	0.60	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	144.49	53.56	-30.01	32.82	-0.17
ROE (%)	78.81	110.09	163.18	42.98	-71.14
ROA (%)	70.75	15.64	26.53	29.32	-16.12
EBIT Margin (%)	33.02	21.13	5.73	31.04	-0.77
Net Margin (%)	116.30	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	3.31	24.67	114.85	9.23	12.22
EBIT Growth (%)	-14.50	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	229.08	17.50	378.76	42.89	-115.58
EPS Growth (%)	214.18	26.84	353.27	50.42	-73.87
Book Value Growth (%)	381.87	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	2.20	36.06	-59.76	15.79	-2,869.63
Price / Book Value	2.06	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	5.36	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.09	0.00	0.05	0.00	0.09
Current Ratio	1.95	0.73	2.99	3.46	5.90
Quick Ratio	1.79	0.73	2.32	3.38	5.90
Interest Coverage	15.74	--	1.62	--	-1.72

Operating Efficiency Ratios

	Rigel Pharmaceuticals (RIGL)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	20.25	15.88	21.25	13.74	1.28
Asset Turnover	0.61	0.89	0.37	0.83	0.34
Receivable days	57.95	50.42	85.52	43.48	1.50
Inventory Days	162.96	--	1,056.70	96.17	--
Payable days	98.01	6.26	331.01	147.97	221.81
Cash Conversion Cycle	122.90	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly